1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein
(
- Contribution to journal › Article
- 2017
-
Mark
Gene therapy for Parkinson's disease : Disease modification by GDNF family of ligands
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease
(
- Contribution to journal › Article
- 2012
-
Mark
Dysregulated dopamine storage increases the vulnerability to alpha-synuclein in nigral neurons
(
- Contribution to journal › Article
- 2010
-
Mark
Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease
(
- Contribution to journal › Scientific review
- 2007
-
Mark
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
(
- Contribution to journal › Article
- 2005
-
Mark
Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease
(
- Contribution to journal › Article
- 2001
-
Mark
Restorative and neuroprotective treatment strategies for Parkinson’s disease: tudies on fetal dopamine cell transplants and GDNF delivery by intracerebral injections and recombinant AAV vectors.
2001)(
- Thesis › Doctoral thesis (compilation)
- 2000
-
Mark
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model
(
- Contribution to journal › Article